City

Nanchang (1)

Ningbo (1)

Shanghai (1)

Zunyi (1)

Condition

Neoadjuvant Chemoimmunotherapy (3)

Esophageal Squamous Cell Carcinoma (2)

Adjuvant Therapy (1)

Complete Pathological Response (1)

Non-small Cell Lung Cancer (1)

Overall Status

Recruiting (2)

Not yet recruiting (1)

Sign in for free

Phase

phase 2 (1)

Sponsor

Guo Xufeng (1)

Shanghai Pulmonary Hospital, Shanghai, China (1)

Shanghai Zhongshan Hospital (1)

Collaborator

Ningbo HwaMei Hospital, Zhejiang, China (1)

The First Affiliated Hospital of Nanchang University, Jiangxi, China (1)

Zunyi Medical College (1)

Intervention

ct/pet/wsi-based deep learning signature (1)

neoadjuvant anti-pd-1 (keytruda) plus chemotherapy (1)

tislelizumab (1)

Study Documents

Intervention Type

drug (2)

diagnostic test (1)

Funder Type

Other (3)

Study Type

Interventional (1)

Observational (1)

Observational [Patient Registry] (1)

neoadjuvant chemoimmunotherapy

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy Trial in Shanghai (Tislelizumab)

Recruiting

Esophageal Squamous Cell Carcinoma
+2 more

Tislelizumab

Shanghai, Shanghai, China

Shanghai chest hospital

Sep 24, 2023

Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer

Recruiting

Non-small Cell Lung Cancer
+2 more

CT/PET/WSI-based Deep Learning Signature

Zunyi, Guizhou, China
+2 more

Jun 27, 2023

Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy Trial (neoadjuvant anti-PD-1 (Keytruda) plus chemo)

Not yet recruiting

Esophageal Squamous Cell Carcinoma
Neoadjuvant Chemoimmunotherapy

neoadjuvant anti-PD-1 (Keytruda) plus chemotherapy

(no location specified)

Feb 14, 2023